RenBio’s President & Chief Scientific Officer, Rachel Liberatore, Ph.D., presented at the NIAID Antiviral Antibody Workshop, a meeting focused on advancing antibody therapeutics through innovations in antibody engineering and delivery. During her session, entitled, “Alternative Delivery Platforms: Intramuscular Electroporation of DNA-Encoded ZIKV-117 mAb,” Dr. Libertore discussed RenBio’s MYO Technology™ platform for ultra long-lasting, DNA-based delivery of antibodies, highlighting its potential to enable durable delivery of a highly potent neutralizing antibody against Zika virus.
View the agenda here.